GW&K Investment Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO

Key Points

• GW&K Investment Management LLC established a new stake in BridgeBio, buying 598,237 shares valued at approximately $31,073,000, representing about 0.31% of the company.
• BridgeBio's most recent quarter showed an EPS miss (‑$1.00 vs. consensus ‑$0.75) while revenue beat at $154.18 million, a year‑over‑year increase of about 2,521%.
• The stock trades around $66.17 (1‑year range $28.33–$84.94) with a market cap of $12.83B, ~99.85% institutional ownership, notable insider selling (~164,174 shares, $12.0M over 90 days), and a consensus analyst target of $82.50 ("Moderate Buy").

GW&K Investment Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 598,237 shares of the company's stock, valued at approximately $31,073,000. GW&K Investment Management LLC owned 0.31% of BridgeBio Pharma at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Strs Ohio raised its position in BridgeBio Pharma by 1.1% during the 3rd quarter. Strs Ohio now owns 18,600 shares of the company's stock worth $966,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of BridgeBio Pharma by 28.6% in the third quarter. GAMMA Investing LLC now owns 1,020 shares of the company's stock valued at $53,000 after acquiring an additional 227 shares in the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of BridgeBio Pharma by 22.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company's stock worth $54,000 after acquiring an additional 228 shares during the period. Gabelli Funds LLC raised its holdings in BridgeBio Pharma by 0.3% during the second quarter. Gabelli Funds LLC now owns 73,750 shares of the company's stock worth $3,185,000 after purchasing an additional 250 shares in the last quarter. Finally, Main Management ETF Advisors LLC raised its holdings in BridgeBio Pharma by 1.7% during the second quarter. Main Management ETF Advisors LLC now owns 22,723 shares of the company's stock worth $981,000 after purchasing an additional 372 shares in the last quarter. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Price Performance

NASDAQ BBIO opened at $66.17 on Friday. BridgeBio Pharma, Inc. has a 1-year low of $28.33 and a 1-year high of $84.94. The company has a market capitalization of $12.83 billion, a P/E ratio of -17.51 and a beta of 1.13. The business has a 50 day moving average price of $73.85 and a 200 day moving average price of $65.11.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. The business's quarterly revenue was up 2521.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.40) EPS. On average, research analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Insider Buying and Selling at BridgeBio Pharma

In other BridgeBio Pharma news, Director Randal W. Scott sold 10,000 shares of BridgeBio Pharma stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total transaction of $754,600.00. Following the completion of the transaction, the director owned 11,589 shares in the company, valued at approximately $874,505.94. The trade was a 46.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 28,053 shares of the company's stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $71.39, for a total transaction of $2,002,703.67. Following the completion of the sale, the chief executive officer directly owned 234,451 shares in the company, valued at $16,737,456.89. This trade represents a 10.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 164,174 shares of company stock valued at $12,036,335 over the last 90 days. 18.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

BBIO has been the topic of a number of analyst reports. Sanford C. Bernstein started coverage on BridgeBio Pharma in a report on Thursday, December 11th. They issued an "outperform" rating and a $94.00 price objective on the stock. Truist Financial raised their price target on BridgeBio Pharma from $86.00 to $95.00 and gave the company a "buy" rating in a report on Wednesday, February 25th. Wells Fargo & Company lifted their price target on BridgeBio Pharma from $88.00 to $98.00 and gave the company an "overweight" rating in a research note on Friday, February 13th. HC Wainwright increased their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, February 17th. Finally, TD Cowen reissued a "buy" rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $82.50.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.